Naloxone Advantage NAXVY delivers 74% higher exposure within 2.5 minutes compared with Narcan, signaling a faster overdose reversal option. This performance advantage provides a strong sales message for pharmacies, EMS, and public health programs seeking rapid, effective rescue.

Retail Distribution As an OTC product with a price-competitive profile, NAXVY is positioned for broad retail distribution through national pharmacies, outpatient clinics, and public health purchasing programs. Success will depend on strategic distributor partnerships and co-promotion with safety campaigns.

Scale Manufacturing PINOVA’s automated line can produce up to 3 million units annually, enabling reliable supply for launch and surges. The manufacturing capability could also support contract manufacturing of other nasal-delivery products built on the same swab platform.

Nasal Platform The proprietary nasal swab technology is broadly adaptable to other drugs, creating licensing or co-development opportunities with pharmaceutical partners seeking improved nasal formulations.

Growth Partnerships Lean team and funding support (roughly $6.2M in funding, revenue in the $1–$10M range) position PINOVA to accelerate market access through partnerships with OTC distributors, emergency response programs, and large pharma to scale distribution and validate the product offering.